These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35093934)

  • 1. Pan-cancer analysis reveals NUP37 as a prognostic biomarker correlated with the immunosuppressive microenvironment in glioma.
    He Y; Li J; Shen L; Zhou H; Fei W; Zhang G; Li Z; Wang F; Wen Y
    Aging (Albany NY); 2022 Jan; 14(2):1033-1047. PubMed ID: 35093934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells.
    Liu Z; Wang H; Jia Y; Wang J; Wang Y; Bian L; Liu B; Lian X; Zhang B; Ren Z; Zhang W; Dai W; Gao Y
    Cancer Med; 2021 Aug; 10(15):5218-5234. PubMed ID: 34264013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.
    Xu L; Shao F; Luo T; Li Q; Tan D; Tan Y
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
    Zhong A; Chen T; Xing Y; Pan X; Shi M
    Front Immunol; 2021; 12():758648. PubMed ID: 34745134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer.
    Zhao Q; Liu J
    Front Cell Dev Biol; 2021; 9():754580. PubMed ID: 34966739
    [No Abstract]   [Full Text] [Related]  

  • 7. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients.
    Tang Z; Yang Y; Chen W; Li E; Liang T
    J Transl Med; 2022 Jan; 20(1):49. PubMed ID: 35093119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
    Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
    Front Immunol; 2022; 13():837512. PubMed ID: 35401558
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 10. Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors.
    Zhu M; Wang X; Zhang Q; Xie C; Wang T; Shen K; Zhang L; Zhou X
    Aging (Albany NY); 2024 Feb; 16(3):2563-2590. PubMed ID: 38315450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma.
    Zhong A; Chen T; Zhou T; Zhang Z; Shi M
    Front Pharmacol; 2021; 12():728420. PubMed ID: 34744715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
    Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
    Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Omics Pan-Cancer Analysis of Procollagen N-Propeptidase Gene Family of ADAMTS as Novel Biomarkers to Associate with Prognosis, Tumor Immune Microenvironment, Signaling Pathways, and Drug Sensitivities.
    Chen Y; Xiao C; Fan Q; Zhang Y; Huang Q; Ou Y
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):151. PubMed ID: 38682182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of EphA2 in pan-cancer: A prognostic biomarker associated with cancer immunity.
    Li Y; Fei H; Xiao Z; Lu X; Zhang H; Liu M
    Clin Exp Pharmacol Physiol; 2024 Aug; 51(8):e13902. PubMed ID: 38886133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
    Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
    Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-cancer analysis identifies FAM49B as an immune-related prognostic maker for hepatocellular carcinoma.
    Xu F; Chen J; Huang D
    J Cancer; 2022; 13(1):278-289. PubMed ID: 34976189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pan-Cancer Crosstalk Between the
    Xie R; Yuan M; Jiang Y
    Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.